

Gastroenterology

Volume 166 / Issue 5

May 2024

www.gastrojournal.org

TABLE OF
CONTENTS

Contents

ON THE COVER



Transcriptomic Microenvironment Classification for Pancreatic Cancer. See article by George, et al, page 859 for additional information.

COMMENTARIES

- 717 The Multi-dimensional Challenge of Poor Oral Health in Cirrhosis—Disparities and Solutions**
M. M. Lauridsen, L. L. Grønkjær, S. Khraibut, N. Patel, J. G. Deeb, and J. S. Bajaj

MENTORING, EDUCATION, AND TRAINING CORNER

- 723 Developing a Mentoring Network to Navigate Fellowship and Beyond: Moving From “Mentor” to “Mentors”**
K. A. Cameron, T. J. Rodrigues, and R. N. Keswani

EDITORIALS

- 728 How Close Is Close Enough? Improving Observational Study Design to Compare the Effectiveness of Health Interventions**
S. K. Murthy
See Lujan R et al on page 815.

- 730 A Baby Step or a Real Giant Stride: Histomic Enabled by Artificial Intelligence to Predict Treatment Response in Pediatric Patients With Ulcerative Colitis**
M. Iacucci, Y. Maeda, and S. Ghosh
See Liu X et al on page 921.

GASTRO CURBSIDE CONSULT

- 733 Watery Diarrhea and Various and Variable Lesions in the Intestine**
Y. Zhang, C. Jia, and Q. Wang

Video Related article in CGH Hot Papers From New Investigators

CME quiz Editorial accompanies this article Additional online content available Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2024 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

- 738 An Unusual Cause of Severe Wall Thickening and Stenosis of the Sigmoid Colon Accompanied by Polyposis**
S. Masaki, H. Honjo, and T. Watanabe

ELECTRONIC GASTRO CURBSIDE CONSULT

For a full list, please see the table of contents online at www.gastrojournal.org.

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

- 743 Colon Polyp Surveillance: Separating the Wheat From the Chaff**
B. A. Sullivan and D. A. Lieberman

- 758 Colonoscopy vs the Fecal Immunochemical Test: Which is Best?**
D. J. Robertson, D. K. Rex, O. Ciani, and M. F. Drummond

ORIGINAL RESEARCH

Full Reports

GI Cancer

- 772 Oncogenic Fatty Acid Metabolism Rewires Energy Supply Chain in Gastric Carcinogenesis**
Y. Won, B. Jang, S.-H. Lee, M. L. Reyzer, K. S. Presentation, H. Kim, B. Caldwell, C. Zhang, H. S. Lee, C. Lee, V. Q. Trinh, M. C. B. Tan, K. Kim, R. M. Caprioli, and E. Choi

Oncogenic gene activation in gastric proenzyme-secreting cells can lead to the carcinogenic process in gastric cancer development. Metabolic changes are essential for precancerous cell lineage progression into cancerous cells.

- 787 Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention**
A. M. Bolivar, F. Duzagac, N. Deng, L. Reyes-Urbe, K. Chang, W. Wu, C. M. Bowen, M. W. Taggart, S. Thirumurthi, P. M. Lynch, Y. N. You, J. Rodriguez-Pascual, S. M. Lipkin, S. Kopetz, P. Scheet, G. A. Lizee, A. Reuben, K. M. Sinha, and E. Vilar

This study provides the combined mutational and transcriptomic landscape along with a catalog of immunologically validated neoantigens in Lynch syndrome colonic precancers and tumors that will facilitate cancer immunoprevention strategies.

Inflammatory Bowel Disease

- 802 Histologic Remission in Inflammatory Bowel Disease and Female Fertility: A Nationwide Study**
K. Mårild, J. Söderling, O. Stephansson, J. Axelrad, J. Halfvarson, SWIBREG Study Group, G. Bröms, J. Marsal, O. Olén, and J. F. Ludvigsson

The findings of this nationwide study suggest that achieving histologic remission of inflammatory bowel disease may improve the chances of conceiving a child, even among women with clinically quiescent disease.

- 815 Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort**
R. Lujan, R. Buchuk, G. Focht, D. Yogev, S. Greenfeld, A. Ben-Tov, Y. L. Weisband, N. Lederman, E. Matz, S. Ben Horin, I. Dotan, D. Nevo, and D. Turner

See editorial on page 728.

A small advantage for early initiation of biologics was demonstrated in Crohn's disease, but this was not the case in ulcerative colitis.

Intestinal Inflammation

826 **Interleukin 21 Drives a Hypermetabolic State and CD4⁺ T-Cell-Associated Pathogenicity in Chronic Intestinal Inflammation**

A. O. Bamidele, S. K. Mishra, G. Piovezani Ramos, P. Hirsova, E. E. Klatt, L. M. Abdelrahman, M. R. Sagstetter, H. M. Davidson, P. J. Fehrenbach, L. Valenzuela-Pérez, H. S. Kim Lee, S. Zhang, A. Aguirre Lopez, A. T. Kurdi, M. S. Westphal, M. M. Gonzalez, J. M. Gaballa, R. L. Kosinsky, H. E. Lee, T. C. Smyrk, G. Bantug, N. M. Gades, and W. A. Faubion Jr

Interleukin 21 induces metabolic alterations and acquisition of an inflammatory-like phenotype by perturbing mitochondria–endoplasmic reticulum crosstalk, thereby diminishing the capacity of Tregs in suppressing inflammatory bowel disease.

Pancreas

842 **Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis**

S. Parte, A. B. Kaur, R. K. Nimmakayala, A. O. Ogunleye, R. Chirravuri, R. Vengoji, F. Leon, P. Nallasamy, S. Rauth, Z. W. Alsafwani, S. Lele, J. L. Cox, I. Bhat, S. Singh, S. K. Batra, and M. P. Ponnusamy

Pancreatic cancer inception and early detection remain elusive. Complex cellular crosstalk transforming normal cells toward tumor development by means of novel cell signaling mechanism has been identified as the potential culprit.

859 **Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma**

B. George, O. Kudryashova, A. Kravets, S. Thalji, S. Malarkannan, R. Kurzrock, E. Chernyavskaya, M. Gusakova, D. Kravchenko, D. Tychinin, E. Savin, L. Alekseeva, A. Butusova, A. Bagaev, N. Shin, J. H. Brown, I. Sethi, D. Wang, B. Taylor, T. McFall, M. Kamgar, W. A. Hall, B. Erickson, K. K. Christians, D. B. Evans, and S. Tsai

Transcriptomic-based tumor microenvironment classification identifies 4 prognostically distinct pancreatic ductal adenocarcinoma subtypes that can serve as a framework for patient selection to precision medicine trials.

872 **A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study**

N. J. Rodriguez, C. S. Furniss, M. B. Yurgelun, C. Ukaegbu, P. E. Constantinou, I. Fortes, A. Caruso, A. N. Schwartz, J. E. Stopfer, M. Underhill-Blazey, B. Kenner, S. H. Nelson, S. Okumura, A. Y. Zhou, T. B. Coffin, H. Uno, M. Horiguchi, A. J. Ocean, F. McAllister, A. M. Lowy, A. P. Klein, L. Madlensky, G. M. Petersen, J. E. Garber, S. M. Lippman, M. G. Goggins, A. Maitra, and S. Syngal

Online genetic education and genetic testing can be used to overcome some health care delivery barriers without negatively affecting anxiety, depression, or cancer worry.

Hepatobiliary

886 **Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma**

M. Lewinska, E. Zhuravleva, L. Satriano, M. B. Martinez, D. K. Bhatt, D. V. N. P. Oliveira, Y. Antoku, F. L. Keggenhoff, D. Castven, J. U. Marquardt, M. S. Matter, J. T. Erler, R. C. Oliveira, B. I. Aldana, R. Al-Abdulla, M. J. Perugorria, D. F. Calvisi, L. A. Perez, P. M. Rodrigues, I. Labiano, J. M. Banales, and J. B. Andersen

Lysyl oxidase expression is enhanced in cholangiocarcinoma tumors and predictive of poor survival. Lysyl oxidase is found mainly in cancer-associated fibroblasts, resident stromal cells responsible for shaping the tumor microenvironment. Lysyl oxidase inactivation in vivo shows diminished cholangiocarcinoma burden in murine livers. Therefore, targeting lysyl oxidase may be a promising therapeutic strategy in cholangiocarcinoma.

902 Sex, Genotype, and Liver Volume Progression as Risk of Hospitalization Determinants in Autosomal Dominant Polycystic Liver Disease

R. Schönauer, D. Sierks, M. Boerrigter, T. Jawaid, L. Caroff, M.-P. Audrezet, A. Friedrich, M. Shaw, J. Degenhardt, M. Forberger, J. de Fallois, H. Bläker, C. Bergmann, J. Gödiker, P. Schindler, B. Schlevogt, R.-U. Müller, T. Berg, I. Patterson, W. J. Griffiths, J. A. Sayer, Genomics England Research Consortium, B. Popp, V. E. Torres, M. C. Hogan, S. Somlo, T. J. Watnick, F. Nevens, W. Besse, E. Cornec-Le Gall, P. C. Harris, J. P. H. Drenth, and J. Halbritter

Autosomal dominant polycystic liver disease is a rare genetic condition mainly due to mutated *PRKCSH* or *SEC63*. Symptomatology is highly variable, ranging from clinically silent courses to severe organ enlargement and sarcopenia. As disease prognostication at early stages is poorly developed, the predictive value of genetic confirmation and liver volumetry for individual disease prediction are investigated. Although *PRKCSH* defects and female sex pointed to aggravated disease, *SEC63* alterations and male sex are associated with milder courses. New clinical tools to inform patients and their physicians to warrant personalized management and rational decision making are proposed.

RESEARCH LETTERS**915 HLA-DQ Diversity Is Associated With Humoral Response to Vaccines in Patients Awaiting or After Liver Transplantation**

C. Féray, V. Allain, C. Desterke, B. Roche, A. Coilly, and S. Caillat-Zucman

918 A Cross-Institution Protocol for Virtual, Transdiagnostic, Group Gut-Directed Hypnotherapy

J. K. Salwen-Deremer, J. Gerson, K. N. Tomasino, M. R. Craven, A. U. Pandit, and O. S. Palsson

921 Machine Learning-Based Prediction of Pediatric Ulcerative Colitis Treatment Response Using Diagnostic Histopathology

X. Liu, S. Prasath, I. Siddiqui, T. D. Walters, L. A. Denson, PROTECT Consortium, and J. Dhaliwal

See editorial on page 730.

AGA SECTION**925 Our New President—Maria T. Abreu, MD, AGAF**

U. Mahadevan, M. Dubinsky, and I. Dotan

CLINICAL PRACTICE UPDATES**930 AGA Clinical Practice Update on Diagnosis and Management of Cannabinoid Hyperemesis Syndrome: Commentary**

A. Rubio-Tapia, R. McCallum, and M. Camilleri

GASTRO DIGEST**935 Pharmacotherapy in Managing Alcohol-Use Disorder**

B. H. Mullish

935 Amitriptyline for the Management of Irritable Bowel Syndrome in Primary Care

M. G. Shiha and I. Aziz

936 Survival of the Fittest: Clonal Selection of Somatic Mutations Reveals Targets to Abate Chronic Liver Injury

N. M. Niemi and B. J. DeBosch

- 937 **Beyond Time and Space: Charting Dynamic Evolution of Sporadic Colorectal Cancer**
P. Lombardi and D. J. Pinato

CORRESPONDENCE

- 939 **The Surveillance for Presumed BD-IPMN of the Pancreas**
H. Deng, W. Dou, and Y. Pan
- 940 **Reply**
F. Casciani, T. Pollini, and R. Salvia
- 941 **Randomized Controlled Trials in Celiac Disease: Expressing the Patient's Voice**
D. G. Silberg, J. Dubow, and A. Bast
- 942 **Reply**
B. Lebwohl, C. Ma, and J. A. Murray
- 943 **Comment Regarding "Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus"**
H. Zhang
- 943 **Antireflux Surgery and the Risk of Progression in Barrett's Esophagus: The Jury Is Still Out**
S. Samo and F. Hamo
- 944 **Exploring the Impact of Antireflux Treatment on Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus: Insights from a Mendelian Randomization Study**
Z. Li and K. Yang
- 945 **Reply**
J. H. Åkerström, G. Santoni, and J. Lagergren
- 946 **Potential of Serum Glycoproteome Profiling in Prediction of Advanced Adenomas and Colorectal Carcinoma: Individual Heterogeneity Should Be Taken Into Account**
R. Qu, Z. Zhang, and W. Fu
- 947 **Corrections**